EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings (NCT07056036) | Clinical Trial Compass
CompletedNot Applicable
EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings
United States51 participantsStarted 2024-11-01
Plain-language summary
The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is:
Does the treatment with EXOMIND (BTL-699-2) device improve willpower, self-control and food cravings?
Participants will be asked to:
* Undergo six treatments
* Complete the Brief Self-control Scale
* Complete the Food Cravings Questionnaire - Trait
* Complete the Therapy Comfort Questionnaire
* Complete the Subject Satisfaction Questionnaire
Who can participate
Age range22 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \> 22 years
* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb
* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement of willpower and self-control and rI eduction of food cravings, including non-invasive brain stimulation treatments other than the study procedure during study participation
* Subjects willing and able to maintain their regular (pre-procedure) exercise regimen without affecting significant change in either direction during study participation
* Willingness to comply with study instructions and to return to the clinic for the required visits
* Women of child-bearing potential\* are required to use birth control measures during the whole duration of the study
* If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry
Exclusion Criteria:
* Electronic implants (Implanted stimulator devices in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), deep brain stimulators, cochlear implants, ocular implant, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, neurostimulators. Contraindicated use could result in serious inj…
What they're measuring
1
Assessment of Change in Willpower and Self-control